Zevra Therapeutics (ZVRA) Q1 2026 Earnings
How Did ZVRA Stock React to Q1 2026 Earnings?
S&P 500 over the same 30 days: +0.75%.
Did ZVRA Beat Earnings? Q1 2026 Results
Yes. Zevra Therapeutics reported Q1 2026 earnings of $0.60 a share on May 6, 2026, beating the $0.08 consensus estimate by 616.0%. Revenue was $36.2M against a $32.0M estimate.
Zevra Therapeutics posted a dramatically transformed quarter in Q1 2026, swinging to GAAP net income of $37.89 million, or $0.60 per diluted share, compared to a net loss of $3.10 million a year ago, as revenue surged 77.5% to $36.22 million on the strength of its rare disease commercial portfolio. The headline driver was MIPLYFFA, the company's treatment for Niemann-Pick disease type C, which generated $24.60 million in net revenue and continues to gain traction with 170 cumulative prescription enrollment forms since launch. A $43.31 million gain from the $50.00 million sale of its SDX portfolio to Commave Therapeutics amplified the bottom line, while the simultaneous retirement of $63.10 million in term loan debt left Zevra with a clean balance sheet and $236.80 million in cash and securities. Analysts tracking the stock have flagged its rare disease positioning as a key growth catalyst. Looking ahead, the company expects an FDA meeting in the second half of 2026 to explore accelerated development pathways for celiprolol in vascular Ehlers-Danlos Syndrome.
- MIPLYFFA net revenue growth driving 78% year-over-year total revenue increase
- Nine new MIPLYFFA prescription enrollment forms in Q1 2026, 170 cumulative since launch
- Expanded Access Program reimbursements of $10.2 million
- Gain on sale of SDX portfolio contributing $43.3 million to operating income
- Market access stable at 69% of covered lives for MIPLYFFA
“We made meaningful progress across the business in the first quarter, led by continued performance for MIPLYFFA, underscoring its role in addressing the needs of patients with Niemann-Pick disease type C.”
Zevra Therapeutics CEO, on the earnings call
What Was Zevra Therapeutics's Outlook in Q1 2026?
Zevra believes its available financial resources of $236.8 million in cash, cash equivalents and securities are sufficient to execute on its strategic priorities independent from the capital markets. The company expects to hold a follow-up meeting with the FDA in the second half of 2026 to explore pathways to accelerate clinical development of celiprolol for VEDS. The EMA review of the Marketing Authorisation Application for arimoclomol for NPC treatment continues to advance through the standard review process.
ZVRA YoY Financials
| Metric | Q1 2026 | Q1 2025 | Year over year |
|---|---|---|---|
| Revenue | $36.2M | $20.4M | +77.5% |
| Operating Income | $52.1M | $4.4M | +1,072.5% |
| Net Income | $37.9M | $2.7M | +1,322.7% |
ZVRA Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.